TRINITY BIOTECH Business Summary

Trinity Biotech PLC (TRIB) is a commercial-stage biotechnology firm that generates revenue through the development, manufacturing, and global marketing of clinical diagnostic systems, including both reagents and instrumentation. The company operates primarily across three segments: Diabetes Management, Human Diagnostics, and an emerging Wearable Biosensor division. Its core product portfolio features the Premier Hb9210™ HbA1c analyzer—which holds the prestigious IFCC Gold Classification for 2026—and a suite of point-of-care (POC) and laboratory tests for infectious diseases (e.g., HIV, Hepatitis), autoimmune disorders, and clinical chemistry. Trinity Biotech competes directly with industry giants such as Abbott Laboratories, Bio-Rad Laboratories, and DiaSorin, as well as DexCom in the continuous glucose monitoring (CGM) space. The company currently occupies a niche market position, pivoting from traditional in-vitro diagnostic (IVD) manufacturing toward a high-margin, technology-led model focused on wearable biosensors and outsourced production. Founded in 1992 by Ronan O'Caoimh and Anthony C. Nicholls, Trinity Biotech is currently led by President and CEO John Gillard, a former CFO who brought a high-pedigree background from Alphabet Inc. (Google) and PWC. The executive team includes Interim CFO Des Fitzgerald, a life sciences specialist formerly of PWC Canada, and Chief Technology Officer Gary Keating, a PhD-qualified scientist with extensive expertise in IVD innovation. The company’s strategic direction is heavily influenced by its primary lender and strategic partner, Perceptive Advisors, which has provided significant capital to fund the development of its "CGM+" wearable technology. The board was further strengthened in late 2025 with the appointment of Paul Tivnan, a veteran in finance and capital markets, as a Non-Executive Director to oversee the firm’s ongoing financial transformation and debt optimization.